spacer
home > ict > Summer 2015
PUBLICATIONS

International Clinical Trials

ict
Summer 2015

   
Text
PDF
Editor’s Comment

From industry's slow but certain adoption of risk-based monitoring, to the digital impact on trial methodologies – Graham Hughes highlights a selection of articles from this edition.
 
view
download pdf
bullet
Regulatory & Business Practice
GCP Audits

Check Points

Jeff Antos from The Weinberg Group offers a guide to Good Clinical Practice audits and how they can be accomplished to meet sponsor expectations, especially given the vast differences in the way they are sold and priced.
 
view
download pdf
bullet
TRIAL MANAGEMENT
Bring Your Own Device

Smart Thinking


It has been slow going for 'bring your own device' in pivotal trials, with industry and regulators erring on the side of caution. But we might now be at a tipping point, with concerns being addressed and conversation giving way to action. Susan M Dallabrida and Karin Beckstrom from ERT report.
 
view
download pdf
Site Performance

Aiming High


High-performing sites equals high-quality research, which is why an ambitious multi-stakeholder initiative is developing much needed global standards for the accreditation of clinical sites to drive excellence. Arti Bajpai, Greg Koski and Mary Tobin at ACRES provide an update.
 
view
download pdf
RBM Implementation

Worth the Effort

Risk-based monitoring promises big savings in research time and cost, yet it is a major change for the industry, with project teams and site staff struggling to adopt and adjust. PPD's Nicole Stansbury outlines how a sponsor-CRO working group can ease the transitional pains.
 
view
download pdf
Site Documentation

On the Record


With digital content and electronic files now commonplace in trials, document risk-based monitoring is the logical next step. Betsy Fallen at Phlexglobal describes how the process is capable of being adapted to the essential documents stored by institutions and investigators.

 
view
download pdf
bullet
eCLINICAL
Electronic Data Capture

Data Values


The industry may be convinced by the benefits of electronic data capture, but lingering concerns over the upfront costs have hampered wider adoption. Glenn Keet at Clinovo argues that new offerings mean many of the perceived barriers are no longer relevant.
 
view
download pdf
bullet
Regional trials
Market Overview: UAE

United by Research


Offering a snapshot of the United Arab Emirates, Adhiti Sharad Kumar outlines how its regulatory set-up, which helps maintain ethical, good clinical practice-compliant studies, is catching the eye of global pharma.
 
view
download pdf
bullet
data management & statistical analysis
Patient-Centric Solutions

Listen Up

Today's ePRO solutions are helping make the patient-centric philosophy a reality, delivering direct feedback and data straight from patients' fingertips. Rauha Tulkki-Wilke at CRF Health says it is a 'win-win', bringing better designed trials and more satisfi ed participants.
 
view
download pdf
mHealth Technologies

On the Go


Tech-savvy patients are providing rich, real-time data for trials as the mHealth revolution marches on. There may still be outstanding questions around privacy but, as Adam Curran of ArisGlobal explains, smartphones are the new medical device.
 
view
download pdf
PRO Data

Reaching Out


The value of patient-reported outcomes data that can address the cost and quality of healthcare is firmly established in drug development. But while it gives real-world evidence, beyond the safety and efficacy data from trials, there are hurdles to address, says Chitra Lele from Sciformix.
 
view
download pdf

Training & Development
Staff Competency

Up to the Job?


Lack of competence among clinical research staff can scupper a trial and jeopardise the rights and safety of patients. But, as IAOCR's Martin Robinson recognises, the industry is wising up to the use of competency frameworks that objectively assess and manage an individual's performance.
 
view
download pdf
bullet
Reviews
Event Review: DIA EuroMeeting

State of the Union


The 27th DIA EuroMeeting in Paris explored all manner of innovation – including the electronic health record revolution and Big Data invading life sciences – although regulatory affairs was a dominant presence. ICT's Graham Hughes reports.

 
view
download pdf

Trial Design
mAb Trials

Fail Safe


A pivotal study is looking to target diseased cells while sparing healthy tissues, to tackle the most common malignant myeloid disorder in adults – and there are substantial design issues to sidestep. Dragan Cicic and David Gould of Actinium Pharmaceuticals have more.
 
view
download pdf

Interview
Q&A: Nucleic Acid Therapeutics

Full of Life


With nucleic acid therapeutics set to rekindle drug discovery efforts for rare and multi-system diseases, Marina Biotech's Michael French tells ICT it is only a matter of time until we see multiple approvals on the market.
 
view
download pdf
Q&A: Statistical Monitoring

Central Time


Smart algorithms are far better than humans at detecting data issues, says Marc Buyse of CluePoints. In conversation with ICT, he sets out how centralised statistical monitoring can be an engine for a more effective risk-based approach.
 
view
download pdf
End Point

Hitting the Headlines


In his new closing column, Graham Hughes says pharma's efforts to rebuild a battered reputation are not being helped by misleading media reports that fail to register its role in breakthrough R&D.
 
view
download pdf
   
spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August and November

News and Press Releases

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

Industry Events

Nordic Life Science Days 2018

10-12 September 2018, Stockholm Waterfront Conference Center, Sweden

The Nordic way of doing life science business NLSDays offers networking and knowledge for anyone interested in the Nordic life science, biotechnologies, pharmaceuticals, medical devices and e-health business. We offer plenty of opportunities to connect.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement